在2q14.2的骨质疏松易感SNP rs188303909通过调节DNA甲基化和E2F6结合来调节EN1表达
Ya Wang1,2, Xinyao Huang1, Qiongdan Zhang1
1Hubei Key Laboratory of Genetic Regulation and Integrative Biology, School of Life Sciences, Central China Normal University, Wuhan, Hubei, 430079, China.
概括
一种新的因果SNP,rs188303909,通过调节DNA甲基化和转录因子E2F6结合来调节骨质疏松基因EN1. 这种机制揭示了EN1如何影响骨密度,并为骨质疏松症精准医学提供了潜在的治疗点.
科学领域:
- 骨代谢的遗传学和表观遗传学.
- 骨质疏松症病原的分子机制.
背景情况:
- 全基因组关联研究 (GWAS) 已经将2q14.2位点与骨质疏松风险联系起来,该位点位于EN1基因附近.
- 正确的因果单核酸多态 (SNP) 和驱动这些关联的功能机制在很大程度上是未知的.
- 由转录因子EN1调节的下游目标基因的特征也很差.
研究的目的:
- 确定2q14.2位点对骨质疏松风险负责的因果SNP.
- 阐明这个SNP影响EN1表达的功能机制.
- 在骨形成的背景下,确定EN1调节的目标基因.
主要方法:
- 功能性基因组学和表观基因组学分析的整合,以确定因果性SNP.
- 实验室功能实验以评估已识别的SNP对基因表达的调节作用.
- 对转录因子结合和DNA甲基化模式的分析.
- 调查EN1与GWAS主要SNP的相互作用及其对下游基因表达的影响.
主要成果:
- 鉴定了rs188303909,一个CpG-SNP,作为2q14.2位点的骨质疏松症的因果SNP.
- 证明非甲基化rs188303909通过调节E2F6结合,作为EN1表达的远端增强剂.
- 证据表明,在rs188303909的DNA甲基化减弱了E2F6对EN1的激活作用.
- 发现EN1通过结合骨质疏松症GWAS导致SNPsrs4869739和rs4355801上调调节CCDC170和COLEC10的表达,促进骨的形成.
结论:
- CpG-SNP rs188303909是在2q14.2骨质疏松症敏感位点的一个因果变异.
- Rs188303909通过通过DNA甲基化和E2F6结合调节的等位基因特异增强剂活性调节EN1表达.
- 通过特定的GWAS SNPs,EN1通过上调CCDC170和COLEC10的表达,在骨形成中发挥作用.
- 这些发现提供了对EN1在骨质疏松症中的作用的机制性见解,并突出了其作为治疗点的潜力.
相关概念视频
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Single Nucleotide Polymorphisms-SNPs
15.1K
A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
15.1K


